NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE226999 Query DataSets for GSE226999
Status Public on Mar 13, 2023
Title The impact of PD-1 antibody or G-CSF antibody on the immune system and the hematopoiesis of TNBC mice
Organism Mus musculus
Experiment type Expression profiling by high throughput sequencing
Summary Triple negative breast cancer (TNBC) is the most intractable subtype of breast cancer. Inhibitors of programmed cell death protein-1 (PD-1) or its ligand PD-L1 have been considered as promising treatment for TNBC patients. However, only a minor subset of TNBC patients benefits from the monotherapy. An analysis of how PD-1/PD-L1 blockage affect immune activities in TNBC tumor-bearing mice could provide insights for it limitation. G-CSF was known to be highly elevated in TNBC cells, and affecting hematopoiesis and the immune system. Spleen is an immune organ and with extramedullary hematopoiesis in TNBC mice. Here we analyzed splenocyte gene expressions changed by administration of either PD-1 antibody or G-CSF antibody in both 4T1 tumor bearing mice and non-tumor control mice. TNBC tumor significantly changed gene expressions in splenocytes, which is consistent with a significant change in splenocyte composition. These genes were enriched in immune related pathways. Anti-PD-1 antibody treatment had limited impact on spleen immune cells composition and splenocyte gene expressions. The most affected genes were enriched in metabolism and extracellular matrix related pathways. Anti-G-CSF antibody treatment had higher impact on the splenocyte gene expression profile, making it more like the gene expression profile in the non-tumor control mice.
 
Overall design Mammary pads of Balb/c female mice were orthotopically implanted with 4T1 cells on day 0 and mice were administered with G-CSF antibody, PD-1 antibody, or anti-IgG dissolved in PBS through intraperitoneal on day 18, day 21, day 24 at a dose of 10 mg/kg. At the endpoint of day 29, We collected splenocytes from mice bearing 4T1 tumor or not and performed RNA-seq by using Illumina NovaSpeq 6000 platform.
 
Contributor(s) Ma M, Yang X, Li F, Chu M, Hong X, Pei L, Ye L, Jiang Z, Liu S, Cui H, Xie Y
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Mar 09, 2023
Last update date Mar 13, 2023
Contact name Ying Xie
E-mail(s) sherryyx36@shutcm.edu.cn
Phone 18017353644
Organization name Shanghai University of Traditional Chinese Medicine
Department School of public Health
Street address 725 South Wanping Road, Shanghai
City Shanghai
State/province Shanghai
ZIP/Postal code 200032
Country China
 
Platforms (1)
GPL24247 Illumina NovaSeq 6000 (Mus musculus)
Samples (18)
GSM7089863 T_I_8
GSM7089864 T_I_12
GSM7089865 T_I_27
Relations
BioProject PRJNA942631

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE226999_tpm.xls.gz 2.0 Mb (ftp)(http) XLS
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap